Related Experiment Video

Updated: May 30, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Vandetanib for the treatment of non-small-cell lung cancer

Hui-li Wong1, Richard H de Boer

  • 1Royal Melbourne Hospital, Department of Medical Oncology, Grattan Street, Parkville, VIC 3050, Australia.

Expert Opinion on Pharmacotherapy
|August 9, 2011
PubMed
Abstract

Insights

Vandetanib shows anti-tumor activity in advanced non-small-cell lung cancer (NSCLC) by inhibiting VEGFR and EGFR. However, Phase III trials did not demonstrate significant survival benefits for this targeted therapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Targeted therapies are increasingly used for advanced non-small-cell lung cancer (NSCLC) due to limitations of conventional chemotherapy.
  • Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) are key targets in NSCLC treatment.
  • Vandetanib is an oral inhibitor targeting both VEGFR and EGFR signaling pathways.

Purpose of the Study:

  • To review the clinical efficacy, safety, and tolerability of vandetanib in advanced NSCLC.
  • To analyze data from randomized Phase III clinical trials evaluating vandetanib.

Main Methods:

  • Review of clinical efficacy and safety data for vandetanib in advanced NSCLC.
  • Focus on randomized Phase III clinical trials comparing vandetanib (monotherapy or combination) with standard treatments.

Main Results:

  • Vandetanib demonstrated anti-tumor activity, including improved objective responses and disease control in NSCLC.
  • Randomized Phase III trials did not show a clinically significant overall survival benefit for vandetanib.

Conclusions:

  • Vandetanib exhibits anti-tumor effects in NSCLC but failed to demonstrate significant survival advantages in Phase III trials.
  • Vandetanib is currently not under further development for NSCLC treatment.

More Related Videos

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...